Dr. Xingli Wang

So that's how we end up winning on small cell lung cancer and also comes out better even than the PD-L1, the two PD-L1s being approved.

And this was the only one, I think, really as a PD-1 drug working so well on small cell lung cancer.

Apart from others, we also, early next year, during the ESCO, you will hear this big news.

We'll change the practice.

We won't be able to tell you the actual results, but it's going to be big.

The adjuvant therapy on the gastric cancer during the operation.

And it could remove the needs of chemotherapy in this type of patients.

And it could end up, I can only tell you, it could change the guideline.

I mean, this is a tough one because I would say in general, it would be similar, maybe slightly better in safety-wise.

From the efficacy point of view, which is not that much different from the Qiskali of Novartis,

And it's not that much different from the other, but it does have a slightly different uniqueness.

One is passing through the blood-brain barrier seems a little bit more because the clinical results does indicate.

I mean, it was approved for first line and second line, the therapy on the lung cancer.

I mean, also the safety profiles also appears to be less aggressive than the current existing drugs.

So I would say with this relatively mild safety profile with similar or in certain aspects slightly better efficacy, I think this drug on the market, you know, it will achieve its value.

Sure.

You know, as I mentioned, monoclonal antibodies are this HER2 is different from the other HER2s.

It's also working on the domain 4.

But same as the truss, but at the same time, it's a different epitope of the same domain, so it comes with slightly different functions.

When it works together, it ends up with a little bit better outcomes, or much better outcomes.